2,3:5,6-di-O-iso-propylidene-α-D-mannofuranose-1-acrylate | 356797-33-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3:5,6-di-O-iso-propylidene-α-D-mannofuranose-1-acrylate
• 英文别名: [(3aS,4R,6R,6aS)-6-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl] prop-2-enoate
• CAS: 356797-33-6
• 化学式: C₁₅H₂₂O₇
• 分子量: 314.335
• InChiKey: UBSLADRFXCIMFW-WSLQDRLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,3-二氯苯甲醛 、 2,3:5,6-di-O-iso-propylidene-α-D-mannofuranose-1-acrylate 在 三乙烯二胺 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以97%的产率得到5-[2,2-dimethyl-(4R)-1,3-dioxolan-4-yl]-2,2-dimethyl-(3aR,6S,6aR)-perhydrofuro[2,3-d][1,3]-dioxol-6-yl 2-[2,3-dichlorophenyl(hydroxy)methyl]acrylate
  参考文献：
  名称：

  Asymmetric Baylis–Hillman reaction using sugar acrylates—synthesis of optically active α-methylene-β-hydroxy alkanoates

  摘要：

  DOI：

  10.1016/s0957-4166(01)00128-8
• 作为产物：
  描述：

  丙烯酰氯 、 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 以81%的产率得到2,3:5,6-di-O-iso-propylidene-α-D-mannofuranose-1-acrylate
  参考文献：
  名称：

  Asymmetric Baylis–Hillman reaction using sugar acrylates—synthesis of optically active α-methylene-β-hydroxy alkanoates

  摘要：

  DOI：

  10.1016/s0957-4166(01)00128-8

文献信息

• Nanoparticles for drug-delivery
  申请人：Turos Edward

  公开号：US20070190160A1

  公开（公告）日：2007-08-16

  This invention relates to polymeric nanoparticles useful for drug delivery with target molecules bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1 nm to 400 nm, more preferably 1 nm to 200 nm, that are dispersed homogeneously in aqueous solution. The target drug/target substance is covalently bonded to the novel polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. This invention also relates to microemulsion polymerization techniques useful for preparing the novel nanoparticles.

  本发明涉及用于药物传递的聚合物纳米粒子，其表面结合有目标分子，其尺寸为最多1000纳米，优选为1纳米至400纳米，更优选为1纳米至200纳米，并在水溶液中均匀分散。目标药物/目标物质与新型聚合物纳米粒子共价结合，以确保它们在体内或体外细胞培养中受到外部干扰，直到它们在细胞内的目标位点暴露出来。本发明还涉及用于制备新型纳米粒子的微乳聚合技术。
• US9149440B2
  申请人：——

  公开号：US9149440B2

  公开（公告）日：2015-10-06
• [EN] NANOPARTICLES FOR DRUG-DELIVERY<br/>[FR] NANOPARTICULES POUR APPORT DE MEDICAMENT
  申请人：UNIV SOUTH FLORIDA

  公开号：WO2005020933A2

  公开（公告）日：2005-03-10

  This invention relates to a unique process for the preparation of polymeric nanoparticles with target molecules bonded to the surface of the particles and having sizes of up to 1000nm, preferably Inm to 400nm, more preferably Inm to 200nm, that are dispersed homogeneously in aqueous solution. To accomplish the above objective, the polymeric nanoparticles of the subject invention are prepared using a novel technique of microemulsion polymerization. The resulting aqueous solution of polymeric nanoparticles is comprised of about 1 to 100 parts per weight of water or buffer, about 1 to 80 parts per weight of polymeric nanoparticles, which the bio-active molecules are conjugated, about 0.001 to 10 parts per weight of emulsifier, and about 0.00001 to 5 parts per weight of radical initiator based on the weight of the solution. In the method of this invention, the target drug/target substance is covalently bonded to the polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell.
• Asymmetric Baylis–Hillman reaction using sugar acrylates—synthesis of optically active α-methylene-β-hydroxy alkanoates
  作者：Palakodety Radha Krishna、V. Kannan、A. Ilangovan、G.V.M. Sharma

  DOI：10.1016/s0957-4166(01)00128-8

  日期：2001.4